<!DOCTYPE html>
<html>
  <body>
<div id="co_document" class="co_documentType-Cases"><div id="co_document_0" class="co_document co_caselawNRS"><input type="hidden" id="co_keyCiteFlagPlaceHolder"><input type="hidden" id="co_document_starPageMetadata" value="{ &quot;citations&quot;: { &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;:&quot;187 F.Supp.3d 483&quot; }, &quot;pubs&quot;: { &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;:&quot;7903&quot; } }" alt="metadata"><div><a href="https://1.next.westlaw.com/Link/Document/Blob/I24CA5B761DD211B288A850001208BA16/187_F.Supp.3d_483.pdf?targetType=NRS&amp;originationContext=pagepdflink&amp;transitionType=DocumentImage&amp;uniqueId=9d0c7286-7afb-4cdb-8abe-f1ea2fcc2b41&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)" class="co_blobLink" type="application/pdf"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/co_pdf-icon.gif" class="co_pdfIcon" alt="PDF">​Original Image of 187 F.Supp.3d 483 (PDF)</a></div><div class="co_cites">187 F.Supp.3d 483</div><input type="hidden" id="co_document_paraNumbersSourceCiteMetadata" value="{ &quot;paraNumbersSourceCite&quot;: &quot;187 F.Supp.3d 483&quot;, &quot;publicationNumber&quot;: &quot;7903&quot; }" alt="metadata"><div class="co_contentBlock co_briefItState co_courtBlock"><div>United States District Court, D. New Jersey.</div></div><div class="co_title"><div class="co_suit"><div class="co_partyLine">OTSUKA PHARMACEUTICAL CO., LTD., Plaintiff,</div><div>v.</div><div class="co_partyLine">TORRENT PHARMACEUTICALS LIMITED, INC., Torrent Pharma Inc., and <a id="co_link_Ie7f3322212be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Search/Results.html?query=advanced%3a+OAID(4298175930)&amp;saveJuris=False&amp;contentType=BUSINESS-INVESTIGATOR&amp;startIndex=1&amp;contextData=(sc.Default)&amp;categoryPageUrl=Home%2fCompanyInvestigator&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f">Hetero Labs Limited</a>, Defendants.</div></div></div><div class="co_docketDate"><div class="co_contentBlock co_briefItState co_docketBlock"><span>Civil Action No. 14-4671 (JBS/KMW)</span></div><div class="co_date"><span>Signed 05/04/2016</span></div></div><div class="co_contentBlock co_briefItState co_synopsis"><h2 id="co_synopsis" class="co_printHeading">Synopsis</h2><div><div class="co_paragraph"><div class="co_paragraphText"><strong>Background:</strong> Patentee brought patent infringement actions under the Hatch-Waxman Act against competitors, claiming that competitors' submissions of abbreviated new drug applications (ANDA) infringed on its patent for an aripiprazole product. Patentee moved to dismiss competitor's antitrust counterclaim.</div></div></div><div class="co_contentBlock co_briefItState co_synopsisHolding"><div class="co_paragraph"><div class="co_paragraphText"><strong>Holdings:</strong> The District Court, <a id="co_link_I01528d20538211e683708ef6ac764092" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0141880501&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Jerome B. Simandle</a>, Chief Judge, held that:</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F32038796653" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">1</a> competitor failed to allege facts showing that it suffered antitrust injury, and</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F42038796653" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">2</a> competitor failed to allege facts showing that its alleged injury resulted from patentee's unlawful or anti-competitive acts.</div></div></div><div class="co_paragraph"><div class="co_paragraphText">Motion granted.</div></div></div><div class="co_contentBlock co_briefItState co_proceduralPostureBlock"><strong>Procedural Posture(s):</strong> Motion to Dismiss.</div><div id="co_headnotes" class="co_headnotes co_fancyHeadnotes"><h2 id="co_headnoteHeader" class="co_headnoteHeader co_printHeading"><span class="co_headnoteHeaderSpan">West Headnotes (5)</span></h2><div class="co_headnotesContentContainer"><div id="co_expandedHeadnotes"><div class="co_headnoteRow" id="co_anchor_2038796653001"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F12038796653"><span class="co_headnoteNumber" id="co_anchor_headNote_1"><a href="#co_anchor_B12038796653" class="co_internalLink">1</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E4FAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Antitrust and Trade Regulation</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ETHAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Injury to Business or Property</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0EQIAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Antitrust and Trade Regulation</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EUKAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963(2)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Causation</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">To plead an antitrust injury, the party must allege facts showing: (1) that it suffered an injury of the type the antitrust laws seek to prevent, for example, anticompetitive behavior, and (2) that the injury resulted from the adversary's unlawful or anti-competitive acts.</div></div><div id="co_headnoteId_203879665300120220422085951" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EDLAC" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;headnoteId=203879665300120220422085951&amp;originationContext=document&amp;transitionType=CitingReferences&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)" title="Cases that cite headnote 1">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba1c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29T</a></span><span class="co_headnoteTopicKey">Antitrust and Trade Regulation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba2c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII</a></span><span class="co_headnoteTopicKey">Antitrust Actions, Proceedings, and Enforcement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba3c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII(B)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII(B)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba4c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk959/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk959</a></span><span class="co_headnoteTopicKey">Right of Action;  Persons Entitled to Sue;  Standing;  Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba5c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk963</a></span><span class="co_headnoteTopicKey">Injury to Business or Property</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba6c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963(1)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk963(1)</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba7c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29T</a></span><span class="co_headnoteTopicKey">Antitrust and Trade Regulation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba8c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII</a></span><span class="co_headnoteTopicKey">Antitrust Actions, Proceedings, and Enforcement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02aba9c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII(B)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII(B)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02abaac24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk959/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk959</a></span><span class="co_headnoteTopicKey">Right of Action;  Persons Entitled to Sue;  Standing;  Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02ababc24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk963</a></span><span class="co_headnoteTopicKey">Injury to Business or Property</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02abacc24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963(2)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk963(2)</a></span><span class="co_headnoteTopicKey">Causation</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2038796653002"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F22038796653"><span class="co_headnoteNumber" id="co_anchor_headNote_2"><a href="#co_anchor_B22038796653" class="co_internalLink">2</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EVLAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Antitrust and Trade Regulation</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ELNAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Injury to Business or Property</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The hallmark for evaluating the plausibility of an allegation of antitrust injury hinges upon whether the allegedly anticompetitive conduct bears consequence for the overall market, rather than only for the individual competitor.</div></div><div id="co_headnoteId_203879665300220220422085951" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EIOAC" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;headnoteId=203879665300220220422085951&amp;originationContext=document&amp;transitionType=CitingReferences&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)" title="Cases that cite headnote 2">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b0c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29T</a></span><span class="co_headnoteTopicKey">Antitrust and Trade Regulation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b1c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII</a></span><span class="co_headnoteTopicKey">Antitrust Actions, Proceedings, and Enforcement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b2c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII(B)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII(B)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b3c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk959/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk959</a></span><span class="co_headnoteTopicKey">Right of Action;  Persons Entitled to Sue;  Standing;  Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b4c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk963</a></span><span class="co_headnoteTopicKey">Injury to Business or Property</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b5c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk963(1)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk963(1)</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2038796653003"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F32038796653"><span class="co_headnoteNumber" id="co_anchor_headNote_3"><a href="#co_anchor_B32038796653" class="co_internalLink">3</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E6OAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Antitrust and Trade Regulation</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EEBAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972(5)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Injury to business or property</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Competitor failed to allege facts showing that it suffered injury from anticompetitive behavior, as required to plead antitrust injury, where its antitrust claim against patentee rested exclusively upon its individual incurrence of defense costs in patentee's infringement action claiming that competitor's abbreviated new drug application (ANDA) infringed on its patent.</div></div><div id="co_headnoteId_203879665300320220422085951" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ETBAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;headnoteId=203879665300320220422085951&amp;originationContext=document&amp;transitionType=CitingReferences&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)" title="Cases that cite headnote 3">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b7c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29T</a></span><span class="co_headnoteTopicKey">Antitrust and Trade Regulation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b8c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII</a></span><span class="co_headnoteTopicKey">Antitrust Actions, Proceedings, and Enforcement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2b9c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII(B)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII(B)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2bac24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk972</a></span><span class="co_headnoteTopicKey">Pleading</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2bbc24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972(2)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk972(2)</a></span><span class="co_headnoteTopicKey">Complaint</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02d2bcc24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972(5)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk972(5)</a></span><span class="co_headnoteTopicKey">Injury to business or property</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2038796653004"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F42038796653"><span class="co_headnoteNumber" id="co_anchor_headNote_4"><a href="#co_anchor_B42038796653" class="co_internalLink">4</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EFCAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Antitrust and Trade Regulation</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EJEAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972(5)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Injury to business or property</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Competitor failed to allege facts showing that its alleged injury, that is, incurrence of defense costs, resulted from patentee's unlawful or anti-competitive acts, as required to plead antitrust injury, where it did not allege that patentee's conduct in bringing infringement action claiming that its abbreviated new drug application (ANDA) infringed on patent for aripiprazole product had somehow harmed competitive landscape, nor that those costs prevented it from pursuing its entry into aripiprazole market.<input type="hidden" id="co_docMarker_0"></div></div><div id="co_headnoteId_203879665300420220422085951" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EYEAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;headnoteId=203879665300420220422085951&amp;originationContext=document&amp;transitionType=CitingReferences&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)" title="Cases that cite headnote 4">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c0c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29T/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29T</a></span><span class="co_headnoteTopicKey">Antitrust and Trade Regulation</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c1c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII</a></span><span class="co_headnoteTopicKey">Antitrust Actions, Proceedings, and Enforcement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c2c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29TXVII(B)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29TXVII(B)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c3c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk972</a></span><span class="co_headnoteTopicKey">Pleading</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c4c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972(2)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk972(2)</a></span><span class="co_headnoteTopicKey">Complaint</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c5c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/29Tk972(5)/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">29Tk972(5)</a></span><span class="co_headnoteTopicKey">Injury to business or property</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2038796653501"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_2038796653"><span class="co_headnoteNumber" id="co_anchor_headNote_5">5</span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EIFAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EGGAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">In general;  utility</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">US Patent <a id="co_link_I63a4c470c24411ecabb4f52925cef7f9" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032658641&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=Iba14a4c08e8011e380e2b42d53720a0a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">8,642,760</a>. Cited.</div></div><div id="co_headnoteId_203879665350120220422085951" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EVGAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;headnoteId=203879665350120220422085951&amp;originationContext=document&amp;transitionType=CitingReferences&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)" title="Cases that cite headnote 5">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c6c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c7c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291X/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">291X</a></span><span class="co_headnoteTopicKey">Patents Enumerated</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7b02f9c8c24411eca609cd96cb80bf26" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I973c5aa012be11e6981be831f2f2ac24&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">291k2091</a></span><span class="co_headnoteTopicKey">In general;  utility</span></div></div></div></div></div></div><div class="co_clear"></div></div></div></div><div> </div></div><a id="co_headnotesEnd"></a><h2 class="co_attorneyBlockLabel co_printHeading co_briefItState" id="co_attorneysAndLawFirms">Attorneys and Law Firms</h2><div class="co_contentBlock co_briefItState co_attorneyBlock"><div> <span class="co_starPage" id="co_pp_sp_7903_484"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;484&quot; }" alt="metadata">*484</span> <a id="co_link_Iac294fa0390f11e69ab9ba805c15b145" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0446688101&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Brian Ronald Zurich</a>, <a id="co_link_Iac294fa1390f11e69ab9ba805c15b145" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0390397101&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Christopher P. Soper</a>, <a id="co_link_Iac294fa2390f11e69ab9ba805c15b145" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0358577701&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Melissa Anne Chuderewicz</a>, Pepper Hamilton LLP, Princeton, NJ, for Plaintiff.</div><div><a id="co_link_Iacb40370390f11e69ab9ba805c15b145" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0424406001&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Claire J. Evans</a>, Wiley Rein LLP, Washington, DC, <a id="co_link_Iacb40371390f11e69ab9ba805c15b145" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0476277201&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Michael Cross</a>, <a id="co_link_Iacb40372390f11e69ab9ba805c15b145" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0206819301&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">James E. Cecchi</a>, Carella, Byrne, Cecchi, Olstein, Brody &amp; Agnello, P.C., Roseland, NJ, <a id="co_link_Iacb40373390f11e69ab9ba805c15b145" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0128615401&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Michael S. Weinstein</a>, Cole Schotz P.C., Hackensack, NJ, for Defendants.</div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_opinion"></h2><div class="co_docDelivery_dottedLine"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionLead" id="co_anchor_I7b036ef2c24411eca609cd96cb80bf26"><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock x_section" id="co_anchor_I7b1214f1c24411eca609cd96cb80bf26"><div id="co_anchor_I7b1214f1c24411eca609cd96cb80bf26_opinionHeader" class="co_headtext"><div class="co_headtext co_hAlign2"><strong>MEMORANDUM OPINION</strong></div></div><div class="co_contentBlock x_leadAuthorLineBlock"><div class="co_contentBlock x_leadAuthorLine"><a id="co_link_I55e5c270136e11e6b63ac694892357e3" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0141880501&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">SIMANDLE</a>, Chief Judge</div></div><div class="co_paragraph"><div class="co_paragraphText">In this Hatch Waxman Act case, <span class="co_underline">see</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="NB35F9A30701711DFB31F9BBFF0245C2B" data-cite-text="35 U.S.C. §§ 271" data-cite="35USCAS271" data-is-illegal-link="False" data-is-unique="True" data-flag-id="statute.unconstitutional.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=NB35F9A30701711DFB31F9BBFF0245C2B&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_I394ce6b04f8311e6b14ac939a5d06ae3" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">35 U.S.C. §§ 271</a>, <a id="co_link_Ie80e5b4112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS281&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">281</a>, Plaintiff Otsuka Pharmaceutical Co, Ltd. (hereinafter, “Otsuka”) advances its position that the abbreviated new drug application (hereinafter, “ANDAs”) of Defendants Torrent Pharmaceuticals Limited, Inc. and Torrent Pharma Inc. (collectively, “Torrent”) infringe the various patents covering Otsuka's aripiprazole product, <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=bdrug&amp;entityId=I37eaf688475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)&amp;ppcid=569feef1fafd4cfea958348c2a18871f" class="co_link co_drag ui-draggable" id="co_link_I37eaf688475111db9765f9243f53508a">Abilify</a><sup>®</sup>.<sup id="co_fnRef_B00012038796653_ID0EZLAE"><a class="co_footnoteReference" href="#co_footnote_B00012038796653">1</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText">In the aftermath of various amendments to the parties' pleadings, Otsuka now moves to dismiss Torrent's Third Counterclaim for “Unlawful Monopolization in Violation of the Sherman Act: Sham Litigation,” on the grounds that its current presence on the newly-formed generic aripiprazole market precludes Torrent from demonstrating the antitrust injury necessary for antitrust standing.<sup id="co_fnRef_B00022038796653_ID0EAOAE"><a class="co_footnoteReference" href="#co_footnote_B00022038796653">2</a></sup> (<span class="co_underline">See</span> Otsuka's Br. at 1-4; Otsuka's Reply at 1-3.) Torrent, in opposition, concedes that it launched a generic aripiprazole product in April 2015, following this Court's decision denying Otsuka's motion for injunctive relief, <span class="co_underline">see</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I852188eae81211e4b4bafa136b480ad2" data-cite-text="Otsuka Pharm. Co. v. Torrent Pharm. Ltd., Inc., 99 F.Supp.3d 461 (D.N.J.2015)" data-cite="" data-pub-num="0007903" data-serial-num="2036087623" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I852188eae81211e4b4bafa136b480ad2&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie82ba74112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036087623&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">Otsuka Pharm. Co. v. Torrent Pharm. Ltd., Inc.</span>, 99 F.Supp.3d 461 (D.N.J.2015)</a>, and  <span class="co_starPage" id="co_pp_sp_7903_485"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;485&quot; }" alt="metadata">*485</span> impliedly acknowledges that its allegations of “exclusionary” conduct no longer fairly buttress its antitrust Counterclaim. (<span class="co_underline">See</span> Torrent's Opp'n at 1-6.) For that reason, Torrent turns its attention to the defense costs incurred in this action as the source of its ongoing antitrust injury. (<span class="co_underline">See</span> <span class="co_underline">id.</span> at 4–6.)</div></div><div class="co_paragraph"><div class="co_paragraphText">The Court has addressed the viability of similar counterclaims in <a id="co_link_Ie848a52112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_649&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_649"><span class="co_underline">Otsuka Pharm. Co. v. Torrent Pharm. Ltd., Inc.</span>, 118 F.Supp.3d 646, 649 (D.N.J.2015)</a><sup id="co_fnRef_B00032038796653_ID0EHRAE"><a class="co_footnoteReference" href="#co_footnote_B00032038796653">3</a></sup> and <a id="co_link_I39a6c6864f8311e6b14ac939a5d06ae3" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">Otsuka Pharm. Co. v. Apotex Corp.</span>, 143 F.Supp.3d 188(D.N.J.2015)</a>, and tracks the discussion in <span class="co_underline"><a id="co_link_Ie848a52b12be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> and <span class="co_underline"><a id="co_link_Idc1d73b04fc811e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Apotex</a></span>. Torrent's commercial launch, coupled with its reliance upon costs of defense as an antitrust injury, however, places the pending action in a contextually different posture from the circumstances addressed in <span class="co_underline"><a id="co_link_Ie848a53012be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> and <span class="co_underline"><a id="co_link_Id050d2704fc811e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Apotex</a></span>.</div></div><div class="co_paragraph"><div class="co_paragraphText">For the reasons that follow, Otsuka's motion will be granted to the extent it seeks dismissal, and Torrent's antitrust Counterclaim will be dismissed without prejudice. The Court finds as follows:</div></div><div class="co_paragraph"><div class="co_paragraphText">1. <strong><span class="co_underline">Factual and Procedural Background</span></strong>.<sup id="co_fnRef_B00042038796653_ID0EGXAE"><a class="co_footnoteReference" href="#co_footnote_B00042038796653">4</a></sup> For purposes of the pending motions, the Court need not retrace the lengthy factual and procedural background of this infringement action. Rather, it suffices to note that, on November 15, 2002, Otsuka obtained Food and Drug Administration (hereinafter, the “FDA”) approval to market its aripiprazole product, <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=bdrug&amp;entityId=I37eaf688475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)&amp;ppcid=569feef1fafd4cfea958348c2a18871f" class="co_link co_drag ui-draggable" id="co_link_I37eaf688475111db9765f9243f53508a_0">Abilify</a><sup>®</sup>, under New Drug Application (hereinafter, “NDA”) No. 21–436. (<span class="co_underline">See generally</span> Third Am. Compl. at ¶¶ 5 &amp; 17.) Despite the exclusivity associated with Otsuka's aripiprazole patents, on June 19, 2015, Torrent filed Abbreviated New Drug Application (hereinafter, “ANDA”) No. 20–1519 with the FDA, seeking approval to market generic aripiprazole tablets in the United States, prior to expiration of Otsuka's Abilify<input type="hidden" id="co_docMarker_1"><sup>®</sup> patents. (<span class="co_underline">See</span> Countercl. at ¶¶ 8-15.) In connection with that filing, and in a subsequent notice to Otsuka, Torrent expressed the view that its generic aripiprazole product would not infringe any valid or enforceable claim of the <a id="co_link_Ie86e559812be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032658641&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=Iba14a4c08e8011e380e2b42d53720a0a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">'760 patent</a>. (<span class="co_underline">See</span> <span class="co_underline">id.</span> at ¶ 14.)</div></div><div class="co_paragraph"><div class="co_paragraphText">2. Despite this representation, Otsuka initiated the pending infringement action, and Torrent's antitrust Counterclaim followed. In the Counterclaim, Torrent alleges, more specifically, that Otsuka has initiated “meritless litigation” in an effort to erect barriers to entry to, and otherwise stifle competition in, the aripiprazole market—a market long monopolized by Otsuka. (<span class="co_underline">Id.</span> at ¶¶ 26-50.) Torrent alleges, in turn, that these “exclusionary, anticompetitive, and unlawful activities ... threaten loss or damage to Torrent” by forestalling, frustrating, and preventing Torrent's ability to compete. (<span class="co_underline">Id.</span> at ¶¶ 49-50.) Against that backdrop, the Court turns to whether  <span class="co_starPage" id="co_pp_sp_7903_486"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;486&quot; }" alt="metadata">*486</span> these allegations plausibly demonstrate an antitrust injury.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F12038796653" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF1">1</a><a id="co_anchor_B12038796653"></a><a href="#co_anchor_F22038796653" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF2">2</a><a id="co_anchor_B22038796653"></a>3. <strong><span class="co_underline">Standard of Review Applicable to Otsuka's Challenge to Torrent's Antitrust Standing</span></strong>.<sup id="co_fnRef_B00052038796653_ID0EG6AE"><a class="co_footnoteReference" href="#co_footnote_B00052038796653">5</a></sup> As explained in <span class="co_underline"><a id="co_link_Ie8a7b51412be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> and <span class="co_underline"><a id="co_link_Ic50356d04fc911e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Apotex</a></span>, “[i]n order to plead an antitrust injury, the party must allege facts showing (1) that it suffered an injury of the type the antitrust laws seek to prevent, e.g., anticompetitive behavior, and (2) that the injury resulted from the adversary's unlawful or anti-competitive acts.” <a id="co_link_Ie8a7b51612be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_652&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_652"><span class="co_underline">Torrent</span>, 118 F.Supp.3d at 652–53</a> (footnote omitted); <span class="co_underline">see also </span><a id="co_link_I201fc5e3d8cc11e6978bcbdcbdd61641" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_191&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_191"><span class="co_underline">Apotex</span>, 143 F.Supp.3d at 191</a> (citations omitted) (relying upon <span class="co_underline"><a id="co_link_I0fa098b04fca11e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> for the same premise). Against this rubric, the “ 'hallmark' for evaluating the plausibility of an allegation of antitrust injury” hinges upon whether the allegedly anticompetitive conduct “ bear[s] consequence for the overall market, rather than only for [the] individual competitor.” <a id="co_link_I201fc5e5d8cc11e6978bcbdcbdd61641" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_194&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_194"><span class="co_underline">Apotex</span>, 143 F.Supp.3d at 194</a> (quoting <a id="co_link_Ie8a7b51c12be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_653&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_653"><span class="co_underline">Torrent</span>, 118 F.Supp.3d at 653</a> (quoting <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="Ibf4abfb390cc11e0af6af9916f973d19" data-cite-text="TransWeb, LLC v. 3M Innovative Props. Co., No. 10–4413, 2011 WL 2181189, at *18 (D.N.J. June 1, 2011)" data-cite="" data-pub-num="0000999" data-serial-num="2025410310" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ibf4abfb390cc11e0af6af9916f973d19&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8a7b52112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2025410310&amp;pubNum=0000999&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">TransWeb, LLC v. 3M Innovative Props. Co.</span>, No. 10–4413, 2011 WL 2181189, at *18 (D.N.J. June 1, 2011)</a>)).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F32038796653" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF3">3</a><a id="co_anchor_B32038796653"></a>4. Application of these principles here requires dismissal of Torrent's antitrust Counterclaim. Indeed, Torrent concedes that its claim rests <span class="co_underline">exclusively</span> upon <span class="co_underline">its</span> individual incurrence of defense costs in this litigation. (<span class="co_underline">See generally</span> Torrent's Opp'n at 3-6.) Torrent's newly-minted theory, however, finds no support in the allegations of Torrent's antitrust counterclaim. (<span class="co_underline">See</span> Counterclaim. at ¶¶ 26-50.) Indeed, Torrent roots its antitrust Counterclaim <span class="co_underline">solely</span> on market exclusion, not the defense costs incurred in defending against this litigation. (<span class="co_underline">See, e.g.</span>, <span class="co_underline">id.</span> at ¶¶ 35-39 (generally alleging that Otsuka's “predatory” conduct evidences an intention to “injure or destroy competition” by prevent new market entrants), ¶¶ 42-45 (generally alleging that Otsuka's “meritless” infringement litigations aim to continue its “monopoliz[ation] [of] the relevant market”), ¶¶ 46-50 (generally alleging that Otsuka's “exclusionary, anticompetitive and unlawful actions” have caused “lost profits and business opportunities”).) This deficiency, standing alone, requires dismissal of Torrent's Counterclaim. <span class="co_underline">See</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="Ib53eb62e07a011dcb035bac3a32ef289" data-cite-text="Bell Atl. Corp. v. Twombly, 550 U.S. 544, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)" data-cite="" data-pub-num="0000708" data-serial-num="2012293296" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ib53eb62e07a011dcb035bac3a32ef289&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_I133611ecc5b211e68646d8bb6824032d" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2012293296&amp;pubNum=0000708&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">Bell Atl. Corp. v. Twombly</span>, 550 U.S. 544, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)</a> (explaining that a plausible complaint must contain allegations concerning each “material elements necessary to sustain recovery”).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F42038796653" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF4">4</a><a id="co_anchor_B42038796653"></a>5. Beyond this, even if the Court broadly construed Torrent's Counterclaim to include allegations directed at costs of defense <span class="co_underline">and</span> determined that these costs constitute a qualifying antitrust injury,<input type="hidden" id="co_docMarker_2"><sup id="co_fnRef_B00062038796653_ID0EEKAG"><a class="co_footnoteReference" href="#co_footnote_B00062038796653">6</a></sup>  <span class="co_starPage" id="co_pp_sp_7903_487"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;487&quot; }" alt="metadata">*487</span> the allegations of Torrent's Counterclaim nowhere tether <span class="co_underline">Torrent's</span> payment of defense costs in this litigation (and the related <span class="co_underline"><a id="co_link_I7ad7d7a04fcb11e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> action) to harm borne by the market-at-large. <span class="co_underline">See</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I6fb3ea992c7511dcaf8dafd7ee2b8b26" data-cite-text="In re Hypodermic Prods. Antitrust Litig., MDL No. 1730, 2007 WL 1959224, at *5 (D.N.J. June 29, 2007)" data-cite="" data-pub-num="0000999" data-serial-num="2012648329" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I6fb3ea992c7511dcaf8dafd7ee2b8b26&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8ead89112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2012648329&amp;pubNum=0000999&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">In re Hypodermic Prods. Antitrust Litig.</span>, MDL No. 1730, 2007 WL 1959224, at *5 (D.N.J. June 29, 2007)</a> (citation omitted) (explaining that “antitrust complaints ... should be liberally construed”). Stated differently, Torrent does not allege that Otsuka's anticompetitive conduct has, through these costs of litigation, somehow harmed the competitive landscape, nor that these costs have prevented Torrent from pursuing its entry into the aripiprazole market. <span class="co_underline">See</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="Ibcdf3c7b79ad11d99c4dbb2f0352441d" data-cite-text="Eichorn v. AT&amp;T Corp., 248 F.3d 131, 140 (3d Cir.2001)" data-cite="" data-pub-num="0000506" data-serial-num="2001326262" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ibcdf3c7b79ad11d99c4dbb2f0352441d&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8ead89312be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001326262&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_506_140&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_506_140"><span class="co_underline">Eichorn v. AT&amp;T Corp.</span>, 248 F.3d 131, 140 (3d Cir.2001)</a> (explaining that an allegation of an antitrust injury must reflect that the challenged activity had an “anti-competitive effect on the [overall] competitive market”). Rather, Torrent's allegations demonstrate little more than that Otsuka's claimed conduct had an adverse financial effect on a <span class="co_underline">particular</span> competitor (namely, Torrent). These limited allegations, accepted as true, however, fail to allege a qualifying antitrust injury. <span class="co_underline"><span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="Ibcdf3c7b79ad11d99c4dbb2f0352441d" data-cite-text="Eichorn v. AT&amp;T Corp., 248 F.3d 131, 140 (3d Cir.2001)" data-cite="" data-pub-num="0000506" data-serial-num="2001326262" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ibcdf3c7b79ad11d99c4dbb2f0352441d&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8ead89412be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001326262&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Id.</a></span> (reasoning that an antitrust injury does not lie unless the allegedly anticompetitive conduct “has a wider impact on the [overall] competitive market”); <span class="co_underline">see also</span> <a id="co_link_Ie8ead89612be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2031489933&amp;pubNum=0004637&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_4637_365&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_4637_365"><span class="co_underline">Irish v. Ferguson</span>, 970 F.Supp.2d 317, 365 (M.D.Pa.2013)</a> (citations omitted) (explaining that the pleaded facts must show “that 'the challenged action has had an actual adverse effect on competition as a whole in the relevant market,'” rather than just an adverse effect on the particular competitor); <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I360cf3a9542211d997e0acd5cbb90d3f" data-cite-text="Brotech Corp. v. White Eagle Int'l Techs. Grp., Inc., No. 03–232, 2004 WL 1427136, at *7 (E.D.Pa. June 21, 2004)" data-cite="" data-pub-num="0000999" data-serial-num="2004632675" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I360cf3a9542211d997e0acd5cbb90d3f&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8ead89b12be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2004632675&amp;pubNum=0000999&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">Brotech Corp. v. White Eagle Int'l Techs. Grp., Inc.</span>, No. 03–232, 2004 WL 1427136, at *7 (E.D.Pa. June 21, 2004)</a> (finding “payment of defense costs” insufficient to allege antitrust injury).</div></div><div class="co_paragraph"><div class="co_paragraphText">6. <strong><span class="co_underline">Conclusion</span></strong>. For all of these reasons, Otsuka's motion to dismiss will be granted, and Torrent's antitrust Counterclaim will be dismissed.<sup id="co_fnRef_B00072038796653_ID0E2SAG"><a class="co_footnoteReference" href="#co_footnote_B00072038796653">7</a></sup> Nevertheless, because Torrent may be able to cure the deficiencies identified within this Memorandum Opinion, the Court will grant Torrent leave to amend with fourteen (14) days, to the extent such an amendment can be made consistent with counsel for Torrent's obligations under <a id="co_link_Ie90cb87012be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000600&amp;cite=USFRCPR11&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Federal Rule of Civil Procedure 11(b)</a> and the holdings of this Memorandum Opinion.<sup id="co_fnRef_B00082038796653_ID0ENTAG"><a class="co_footnoteReference" href="#co_footnote_B00082038796653">8</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText">7. An accompanying Order will be entered.</div></div></div></div></div></div></div><div class="co_parallelCites"><h2 id="co_allCitations" class="co_parallelCitesBlockLabel co_printHeading">All Citations</h2>187 F.Supp.3d 483, 2016-1 Trade Cases P 79,618</div><div id="co_footnoteSection" class="co_footnoteSection co_briefItState"><h2 id="co_footnoteSectionHeader" class="co_footnoteSectionTitle co_printHeading">Footnotes</h2><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;484&quot; }" alt="metadata"><span id="co_footnote_B00012038796653"><a href="#co_fnRef_B00012038796653_ID0EZLAE">1</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">The patents asserted by Otsuka in this infringement action specifically include <a id="co_link_Ie81957c312be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032658641&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=Iba14a4c08e8011e380e2b42d53720a0a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">U.S. Patent Nos. 8,642,760 (“the '760 patent”)</a> and <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I75116ba0fc8611e397cd974c12ec86ef" data-cite-text="8,759,350 (hereinafter, “the '350 patent”)" data-cite="" data-pub-num="0004074" data-serial-num="2033669883" data-is-illegal-link="False" data-is-unique="True" data-flag-id="direct.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I75116ba0fc8611e397cd974c12ec86ef&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie81957c712be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033669883&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=I7511b9c0fc8611e397cd974c12ec86ef&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">8,759,350 (hereinafter, “the '350 patent”)</a>. (<span class="co_underline">See generally</span> Third Am. Compl. at ¶ 5.)</div></div></div></div><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;485&quot; }" alt="metadata"><span id="co_footnote_B00022038796653"><a href="#co_fnRef_B00022038796653_ID0EAOAE">2</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">In the alternative, Otsuka requests that the Court bifurcate and stay Torrent's Counterclaim pending resolution of the primary infringement issues. (<span class="co_underline">See</span> Otsuka's Br. at 5; Otsuka's Reply at 4.)</div></div></div></div><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;485&quot; }" alt="metadata"><span id="co_footnote_B00032038796653"><a href="#co_fnRef_B00032038796653_ID0EHRAE">3</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText"><span class="co_underline"><a id="co_link_I53fcca504fcb11e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> differs from this action (which also involves Torrent) in terms of the patents asserted by Otsuka. More specifically, in this action, as recounted above, Otsuka asserts the <a id="co_link_Ie8585c9012be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032658641&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=Iba14a4c08e8011e380e2b42d53720a0a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">'760</a> and <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I75116ba0fc8611e397cd974c12ec86ef" data-cite-text="8,759,350 (hereinafter, “the '350 patent”)" data-cite="" data-pub-num="0004074" data-serial-num="2033669883" data-is-illegal-link="False" data-is-unique="True" data-flag-id="direct.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I75116ba0fc8611e397cd974c12ec86ef&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8585c9112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033669883&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=I7511b9c0fc8611e397cd974c12ec86ef&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">'350 patents</a>. (<span class="co_underline">See generally</span> Third Am. Compl. at ¶ 5.) In <span class="co_underline"><a id="co_link_Ieb82cc104fc811e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span>, by contrast, Otsuka asserts <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I44929e60df1d11e0b2b1fb440f46accd" data-cite-text="U.S. Patent Nos. 8,017,615" data-cite="" data-pub-num="0004074" data-serial-num="2026146909" data-is-illegal-link="False" data-is-unique="True" data-flag-id="direct.history.strong"><a class="co_inlineKeyCiteFlagLink co_rFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I44929e60df1d11e0b2b1fb440f46accd&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_red_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8585c9512be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2026146909&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=I4492c570df1d11e0b2b1fb440f46accd&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">U.S. Patent Nos. 8,017,615</a> and <a id="co_link_Ie8585c9912be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2031944258&amp;pubNum=0004074&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=PA&amp;docFamilyGuid=I83582f704cd011e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">8,580,796</a>. (<span class="co_underline">See</span> Second Am. Compl. in 14-1078 at ¶ 5.)</div></div></div></div><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;485&quot; }" alt="metadata"><span id="co_footnote_B00042038796653"><a href="#co_fnRef_B00042038796653_ID0EGXAE">4</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">For purposes of the pending motion, the Court accepts as true the version of events set forth in Torrent's Counterclaim, together with matters of public record. <span class="co_underline">See</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="Ieac0d29357a611e4b4bafa136b480ad2" data-cite-text="Schmidt v. Skolas, 770 F.3d 241, 249 (3d Cir.2014)" data-cite="" data-pub-num="0000506" data-serial-num="2034638961" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ieac0d29357a611e4b4bafa136b480ad2&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie886e6a112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2034638961&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_506_249&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_506_249"><span class="co_underline">Schmidt v. Skolas</span>, 770 F.3d 241, 249 (3d Cir.2014)</a>; <span class="co_underline">see also</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I89a3a3d0849311e59a139b8f80c70067" data-cite-text="ACR Energy Partners, LLC v. Polo N. Country Club, Inc., 143 F.Supp.3d 198, 199 n. 2 (D.N.J.2015)" data-cite="" data-pub-num="0007903" data-serial-num="2037538732" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I89a3a3d0849311e59a139b8f80c70067&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_I3a06c0d94f8311e6b14ac939a5d06ae3" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2037538732&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_199&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_199"><span class="co_underline">ACR Energy Partners, LLC v. Polo N. Country Club, Inc.</span>, 143 F.Supp.3d 198, 199 n. 2 (D.N.J.2015)<input type="hidden" id="co_docMarker_3"></a> (same). For that reason, the Court takes note, as a matter of public record, of Torrent's FDA approval to market a generic aripiprazole product, as well as their subsequent commercial launch. <span class="co_underline">See</span> <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="If3edcde56f5f11e196ddf76f9be2cc49" data-cite-text="Gross v. Stryker Corp., 858 F.Supp.2d 466, 482 n. 26 (W.D.Pa.2012)" data-cite="" data-pub-num="0004637" data-serial-num="2027326719" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=If3edcde56f5f11e196ddf76f9be2cc49&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie886e6ab12be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027326719&amp;pubNum=0004637&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_4637_482&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_4637_482"><span class="co_underline">Gross v. Stryker Corp.</span>, 858 F.Supp.2d 466, 482 n. 26 (W.D.Pa.2012)</a> (taking note of FDA product approval information); <span class="co_underline">see also</span> Press Release, U.S. Food and Drug Administration, <em>FDA Approves first generic <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=bdrug&amp;entityId=I37eaf688475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)&amp;ppcid=569feef1fafd4cfea958348c2a18871f" class="co_link co_drag ui-draggable" id="co_link_I37eaf688475111db9765f9243f53508a_1">Abilify</a> to treat mental illnesses</em> (April 28, 2015), <em>available at</em> http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444862.htm.</div></div></div></div><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;486&quot; }" alt="metadata"><span id="co_footnote_B00052038796653"><a href="#co_fnRef_B00052038796653_ID0EG6AE">5</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">As explained in <span class="co_underline"><a id="co_link_Ie8bb642412be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> and <span class="co_underline"><a id="co_link_I651609b04fca11e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Apotex</a></span>, the federal antitrust laws require an antitrust claimant to meet the “prudential requirement” of “ 'antitrust standing.' ” <a id="co_link_Ie8bb642612be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_652&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_652"><span class="co_underline">Torrent</span>, 118 F.Supp.3d at 652</a> (citation omitted). In <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I956cfcc7656b11e287a9c52cdddac4f7" data-cite-text="Ethypharm S.A. France v. Abbott Labs., 707 F.3d 223 (3d Cir.2013)" data-cite="" data-pub-num="0000506" data-serial-num="2029708386" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I956cfcc7656b11e287a9c52cdddac4f7&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8bb642812be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2029708386&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">Ethypharm S.A. France v. Abbott Labs.</span>, 707 F.3d 223 (3d Cir.2013)</a>, the Court of Appeals for the Third Circuit outlined a five-factor test relative to this inquiry, but deemed the second factor, “antitrust injury,” the <span class="co_underline">essential</span> precondition for antitrust standing. <span class="co_inlineKeyCiteFlag co_excludeAnnotations" guid="I956cfcc7656b11e287a9c52cdddac4f7" data-cite-text="Ethypharm S.A. France v. Abbott Labs., 707 F.3d 223 (3d Cir.2013)" data-cite="" data-pub-num="0000506" data-serial-num="2029708386" data-is-illegal-link="False" data-is-unique="True" data-flag-id="negative.indirect.history.mild"><a class="co_inlineKeyCiteFlagLink co_yFlagLg" href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I956cfcc7656b11e287a9c52cdddac4f7&amp;transitionType=InlineKeyCiteFlags&amp;originationContext=docHeaderFlag&amp;Rank=0&amp;RuleBookModeDisplay=False&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><img src="https://i1.next.westlaw.com/StaticContent_2204.1.2004/images/v1/flag_yellow_small.png?ignoreDeliveryNewLine"></a></span><a id="co_link_Ie8bb642912be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2029708386&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_506_232&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_506_232"><span class="co_underline">Id.</span> at 232</a>. Here, the parties focus their analysis only on the issue of antitrust injury, and so the Court need not address the other factors.</div></div></div></div><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;487&quot; }" alt="metadata"><span id="co_footnote_B00062038796653"><a href="#co_fnRef_B00062038796653_ID0EEKAG">6</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">The parties dispute whether costs of defense amount to a recognized antitrust injury. (<span class="co_underline">Compare</span> Torrent's Opp'n at 4-6, <span class="co_underline">with</span> Otsuka's Reply at 3-4.) In <a id="co_link_Ie8ff23e112be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2038258548&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">TransWeb, LLC v. 3M Innovative Properties Co.</span>, 812 F.3d 1295 (Fed.Cir.2016)</a>, the Court of Appeals for the Federal Circuit appears to have recognized, at least impliedly, that costs incurred in defense of an infringement action amount to an injury derived from the antitrust wrong. <a id="co_link_Ie8ff23e212be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2038258548&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_506_1309&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_506_1309"><span class="co_underline">Id.</span> at 1309–12</a>. Thus, although <a id="co_link_I06c703404fcb11e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2038258548&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">TransWeb, LLC</span></a> addressed itself to the issue of recoverable antitrust <span class="co_underline">damages</span>, its broad discussion of defense costs as an injury traceable to the claimed antitrust wrong lends obvious credence to Torrent's position. <span class="co_underline">See <a id="co_link_Ie8ff23e312be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2038258548&amp;pubNum=0000506&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">id.</a></span> Nevertheless, in view of the deficiencies recounted above, the Court need not definitively resolve this issue.</div></div></div></div><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;487&quot; }" alt="metadata"><span id="co_footnote_B00072038796653"><a href="#co_fnRef_B00072038796653_ID0E2SAG">7</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">As a result, the Court need not reach the parties' positions on the bifurcation. In the event Torrent restates its antitrust Counterclaim, the Court would, however, be inclined to follow the path charted in <span class="co_underline"><a id="co_link_Ie91ce51412be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Torrent</a></span> and <span class="co_underline"><a id="co_link_I24165ea04fcb11e6a531fe6c2903cffa" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">Apotex</a></span> by bifurcating and staying the antitrust Counterclaim, pending resolution of the primary patent infringement claims. <span class="co_underline">See</span> <a id="co_link_Ie91ce51612be11e68a55e49225993d34" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036529683&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;fi=co_pp_sp_7903_659&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)#co_pp_sp_7903_659"><span class="co_underline">Torrent</span>, 118 F.Supp.3d at 659-60</a> (bifurcating and staying); <a id="co_link_I3b2b43a84f8311e6b14ac939a5d06ae3" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036870294&amp;pubNum=0007903&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)"><span class="co_underline">Apotex</span>, 143 F.Supp.3d 196</a> (same).</div></div></div></div><div><div class="co_footnoteNumber"><input type="hidden" class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;Sd32a8b904ea511e6b8dfe98612c13f84&quot;, &quot;pageNumber&quot;: &quot;487&quot; }" alt="metadata"><span id="co_footnote_B00082038796653"><a href="#co_fnRef_B00082038796653_ID0ENTAG">8</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">The Court harbors some doubts about whether any amount of pleading supplementation would add life to Torrent's antitrust Counterclaim, particularly given its commercial launch nearly one year ago. Beyond this, the nature and crux of Torrent's allegations appear better aligned with a post-judgment request for attorneys' fees under <a id="co_link_I3b3a85e04f8311e6b14ac939a5d06ae3" class="co_link co_drag ui-draggable" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS285&amp;originatingDoc=I973c5aa012be11e6981be831f2f2ac24&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;ppcid=569feef1fafd4cfea958348c2a18871f&amp;contextData=(sc.UserEnteredCitation)">35 U.S.C. § 285</a>. Nevertheless, the Court leaves open the possibility that amended allegations may bring into focus the basis, if any, for Torrent's post-launch antitrust theory.</div></div></div></div></div><table id="co_endOfDocument"><tbody><tr><td>End of Document</td><td class="co_endOfDocCopyright">© 2022 Thomson Reuters. No claim to original U.S. Government Works.</td></tr></tbody></table></div><input class="co_chunkNumber" type="hidden" value="0"><input id="co_finalChunkMarker" type="hidden"></div>
</body>
<script type="module" defer async>
  import { gatherParts } from '../src/js/westlaw-utils.mjs';
  console.log(gatherParts());
  console.log('Done');
</script>
</html>
